Mahasweta Gooptu

Adult BMT Faculty at Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Interests: Allogeneic transplantation

[Mahasweta Gooptu @MGooptu]

Amazing!!

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[Mahasweta Gooptu @MGooptu]

@AAcosta_MedMD @DanaFarber @MayoHemeOnc @Ash @DrCCutler Congratulations and welcome!

[Mahasweta Gooptu @MGooptu]

Congratulations Moses!! Rising star at DFCI @haematognomist @DanaFarberNews

[ASTCT @ASTCT]

Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: https://t.co/cPWG9iJVl5

[Mahasweta Gooptu @MGooptu]

@haematognomist Congratulations on your new investigator award!! Rising star at DFCI @DanaFarberNews

[ASTCT @ASTCT]

Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: https://t.co/cPWG9iJVl5

[Mahasweta Gooptu @MGooptu]

Transplant Jedi. :D @DrCCutler @miguelperales

[ASTCT @ASTCT]

Congratulations to our 2026 Fellows of ASTCT and past presidents Dr. Corey Cutler and Dr. Miguel-Angel Perales! #Tandem26 @DrCCutler

[Mahasweta Gooptu @MGooptu]

Amazing team effort and leadership!! @DrCCutler

[Dana-Farber @DanaFarber]

We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: https://t.co/BMbN681I8i

[Mahasweta Gooptu @MGooptu]

G.O.A.T. :D

[Dana-Farber @DanaFarber]

Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty. We thank Dr. Soiffer for his continued dedication and leadership, which truly exemplify this honor.

[Mahasweta Gooptu @MGooptu]

80% 1 year overall survival in mismatched unrelated donor transplants all the way down to 4/8 mismatched donors!! #Donorsforall #solvedisparitieswithscience @BrianShafferMD @BronwenShaw @nmdp_org

[Dana-Farber News @DanaFarberNews]

Dr. Mahasweta Gooptu (@MGooptu) @danafarber &@nmdp_org presented results using post-transplant cyclophosphamide to prevent graft-versus-host disease in mismatched unrelated donor transplantation, with about 80% 1-year survival thus expanding access to allotransplant for all patients. #ASH25

[GvHD Hub @gvhd_hub]

CONGRESS | #ASH2025 | POSTER

Mahasweta Gooptu shares results from a Phase II expansion study focusing on PTCy-based GVHD prophylaxis after MMUD PBSC transplantation with reduced-intensity conditioning (N = 193).

The 1-year OS estimate was 79.6%; rates were comparable between HLA 7/8-matched donor recipients and <7/8 matched donor recipients. The 1-year GRFS, 1-year PFS, 1-year CI rate of NRM, and 1-year CI rate of relapse was 49.9%, 70.2%, 12.5%, and 17.3%, respectively.

Follow our live feed for more updates: https://t.co/VFzAJAtDt8

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.

#GvHD #GvHDsm #MedEd #MedicalCongress @MGooptu @DanaFarber

[Antonio Jimenez Jimenez @amjimenezmd]

Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every patient. #ADonorForAll #PTCyRules

[Benlazar S M A @smbenlazar]

How I treat AML relapse after allogeneic HSCT https://t.co/6xckZUl2Rk #AML #leusm

[Mahasweta Gooptu @MGooptu]

@nursariipek @NalanYurtsever1 @YaleIMed @ProjectImg @StoriesImg @IMG_Oncologists @TheNRMP @Ankaratip1945 @IMG_Advocate Wonderful news! Congratulations :)

[ImmunoACT @ActImmuno]

India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.

[Dana-Farber News @DanaFarberNews]

Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.

[Dana-Farber @DanaFarber]

Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.

https://t.co/es1uyusSbL

[Mahasweta Gooptu @MGooptu]

@MediHumdani @ASTCT @drkomanduri @UCSFCancer Congratulations Krishna!! @drkomanduri

[Mahasweta Gooptu @MGooptu]

@sghmd @ASTCT You are a rockstar!

[Mahasweta Gooptu @MGooptu]

Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). @DrCCutler @DanaFarberNews

[Jeff Auletta @JeffAuletta]

Congratulations, Dr. Antin as @ASTCT Lifetime Achievement Award! Well deserved! 2025 @ASTCT @CIBMTR Tandem Meetings #Tandem25

[Talha Badar @TalhaBadarMD]

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia https://t.co/luIJYHzAmt
by Dr. Luskin et al. #leusm #ALL

100% CR.

At day 84, 100% of patients achieved complete cytogenetic remission.

At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.

[Mahasweta Gooptu @MGooptu]

@haematognomist

[AML Hub @AML_Hub]

📝 A recent “how I treat” article published in @BloodJournal explores treatment considerations for post-transplant relapse of AML.

More news: https://t.co/rGZeWbvIaJ

@MGooptu #AMLsm #MedEd